

Date: 4th November, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2025.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Press Release

Alembic Pharmaceuticals Ltd announces financial results for Q2 FY26

Q2 FY26 Revenue growth of 16%; PAT growth of 20%

Vadodara / Mumbai, November 4th, 2025

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September 2025.

Financial Highlights for Q2FY26

- Revenue from operations increased by 16% to Rs.1,910 Cr.
- EBITDA increased by 26% to Rs. 325 Cr
- EBITDA Margin at 17% of revenue
- Reported Profit After Tax at Rs.185 Cr. up by 20%.

Commenting on the results, Mr. Shaunak Amin MD, Alembic Pharmaceuticals Limited, said, *Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16% and pre-R&D EBITDA margin of 26%. Our R&D investment, at around 10% of revenue, reflects our commitment to building a strong pipeline for future growth. We continue to focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery. During the quarter, we completed the acquisition of Utility Therapeutics that provides a segway in to branded drugs in the US.*

Operational Highlights

India Branded Business

- India Branded Business delivered a 5% YoY growth, reaching ₹639 Cr in revenue for the quarter.
- Gynaecology, Ophthalmology and Animal healthcare segments have demonstrated accelerating performance.
- Cough & Cold segments grew in line with market performance, with robust operational execution.
- Successfully introduced 2 new products during the quarter.

ALEMBIC PHARMACEUTICALS LIMITED

International Business

- US Generics grew by 21% to Rs. 566 Cr. for the quarter.
- 3 Launches in the US market during the quarter.
- Ex-US International Generics grew by 31% to Rs. 392 Cr. for the quarter.
- 6 ANDA approvals received during the quarter, 226 Cumulative ANDA approvals.

API Business

- API business grew by 15% to Rs. 261 Cr. for the quarter.

The summary of Total Revenue is as under:

(Rs in Cr.)						
Particulars	Q2 FY26	Q2 FY25	% Change	H-1 FY26	H-1 FY25	% Change
Formulation						
India	639	609	5%	1238	1181	5%
USA	566	467	21%	1089	928	17%
Ex- US	392	298	31%	719	568	27%
API	314	274	15%	575	532	8%
Total	1910	1648	16%	3621	3210	13%

Earnings Call: Alembic Pharmaceuticals Limited will host an investor call at 4:00 pm IST on November 4, 2025, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai: Phone: +91 022- 66953681 Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123